Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationTransplantation, HomologousTransplantation, AutologousStem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseBone Marrow TransplantationStem CellsHematologic NeoplasmsMyeloablative AgonistsHematopoietic Stem Cell MobilizationTreatment OutcomeHematopoietic Stem CellsTransplantation ChimeraTissue DonorsBusulfanGraft SurvivalGranulocyte Colony-Stimulating FactorImmunosuppressive AgentsCord Blood Stem Cell TransplantationLeukapheresisCombined Modality TherapyRecurrenceMelphalanRemission InductionAntigens, CD34Multiple MyelomaHistocompatibility TestingVidarabineWhole-Body IrradiationGraft vs Leukemia EffectCyclophosphamideRetrospective StudiesBlood Component RemovalHistocompatibilityAntineoplastic Combined Chemotherapy ProtocolsLeukemiaCytomegalovirus InfectionsDisease-Free SurvivalGraft vs Tumor EffectLeukemia, Myeloid, AcuteSalvage TherapySurvival AnalysisSurvival RateSiblingsTime FactorsLiver TransplantationEmbryonic Stem CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMesenchymal Stem Cell TransplantationLymphoma, Non-HodgkinLymphocyte DepletionLymphocyte TransfusionMyelodysplastic SyndromesKidney TransplantationAdult Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaAntilymphocyte SerumHematologic DiseasesEtoposideHepatic Veno-Occlusive DiseaseNeoplasm, ResidualAnemia, AplasticFollow-Up StudiesCell TransplantationChimerismAcute DiseaseCytarabineHLA AntigensT-LymphocytesInfectionHodgkin DiseaseImmunocompromised HostCytomegalovirusOpportunistic InfectionsHematopoiesisTransplantation ImmunologyThiotepaTransplantation, IsogeneicVirus ActivationPluripotent Stem CellsCell DifferentiationTransplantationImmunosuppressionPrognosisMinor Histocompatibility AntigensBlood CellsFlow CytometryAntineoplastic Agents, AlkylatingCyclosporineBone Marrow PurgingBone Marrow CellsAntineoplastic AgentsStem Cell NicheBlood Cell CountFatal OutcomeGraft RejectionNeural Stem CellsBlood Donors